UCB to acquire Neurona Therapeutics in a deal worth up to $1.15B, adding NRTX-1001 cell therapy to expand its epilepsy pipeline into regenerative medicine.
Written By: Samiksha Jadhav, BPharm
Reviewed By: Pharmacally Editorial Team
UCB announced on April 17, 2026, that it has entered into a definitive agreement to acquire Neurona Therapeutics, expanding its epilepsy portfolio and marking a strategic move into regenerative medicine. The deal, valued at up to $1.15 billion including milestone payments, reflects UCB’s focus on addressing unmet needs in epilepsy by advancing therapies beyond symptomatic management toward potentially disease-modifying approaches.
The acquisition brings Neurona’s lead asset, NRTX-1001, an investigational regenerative neural cell therapy currently in Phase I/II trials for drug-resistant mesial temporal lobe epilepsy (mTLE). The therapy is designed to restore balance in overactive neural circuits by delivering pluripotent stem cell-derived neurons that produce gamma-aminobutyric acid (GABA). Administered as a single, minimally invasive dose directly into the brain, the approach aims to provide durable seizure reduction by repairing compromised neural networks.
NRTX-1001 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA and PRIME designation from the European Medicines Agency, reflecting its potential to address significant unmet medical need and enabling enhanced regulatory support during development.
UCB CEO Jean-Christophe Tellier stated that the acquisition aligns with the company’s innovation strategy and builds on more than 30 years of leadership in epilepsy, adding that NRTX-1001 could extend this legacy into regenerative medicine with the potential to deliver durable, targeted benefits following a single administration.
Cory R. Nicholas, co-founder and CEO of Neurona Therapeutics, said the company is encouraged by UCB’s recognition of its platform and described UCB as an ideal partner given its global expertise in epilepsy, noting that the transaction could help accelerate development of NRTX-1001 and advance the broader regenerative pipeline.
Under the terms of the agreement, UCB will pay $650 million upfront, with up to $500 million in additional milestone payments. The transaction is subject to customary closing conditions, including antitrust clearance, and is expected to close by the end of the second quarter of 2026.
UCB confirmed that its 2026 financial guidance remains unchanged, with revenue and adjusted EBITDA expected to grow in the high single-digit to low double-digit range at constant exchange rates, excluding potential impacts from U.S. tariffs and pricing policy developments.
Reference
About the Writer
Samiksha Vikram Jadhav is a B.Pharm graduate with a strong academic foundation in pharmaceutical sciences, pharmacology, and drug development. She has a keen interest in healthcare advancements, clinical research, medical writing, and emerging therapies. Her work focuses on presenting developments in the pharmaceutical and healthcare sectors through clear and accurate scientific communication.